Association of the methylene-tetrahydrofolate reductase gene rs1801133 C677T variant with serum homocysteine levels, and the severity of coronary artery disease.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
22 06 2020
Historique:
received: 25 10 2019
accepted: 29 05 2020
entrez: 24 6 2020
pubmed: 24 6 2020
medline: 15 12 2020
Statut: epublish

Résumé

This study aimed to investigate whether the single nucleotide polymorphism C677T (rs1801133) of the methylene-tetrahydrofolate reductase (MTHFR) gene was associated with the risk of coronary artery disease (CAD) and circulating homocysteine (Hcy) levels in Tunisian population. 310 angiografically diagnosed CAD patients and 210 controls were enrolled in this study. The MTHFR C677T (rs1801133) polymorphism was genotyped, and the Hcy concentrations were measured. The severity of CAD was evaluated using the Gensini scoring system. Compared to the CC genotype, the TT genotype confers a higher risk for CAD severity with an OR = 9.07 and 95% CI = 3.78-21.8. The T allele was the predisposing allele for CAD and that it was probably associated with CAD severity. The area under the ROC curve for Hcy was 0.764 (95% CI 0.660 to 0.868, p = 0.001). The receiver operating characteristics curve (ROC) for Hcy showed its useful prediction of CAD. Hcy levels were not significantly associated with CAD severity expressed by Gensini Score (GS). The MTHFR C677T (rs1801133) polymorphism influences circulating Hcy levels. The MTHFR C677T polymorphism and hyperhomocysteinemia could have an important role in the prediction of the presence and not the severity expressed by GS of CAD.

Identifiants

pubmed: 32572074
doi: 10.1038/s41598-020-66937-3
pii: 10.1038/s41598-020-66937-3
pmc: PMC7308346
doi:

Substances chimiques

Homocysteine 0LVT1QZ0BA
MTHFR protein, human EC 1.5.1.20
Methylenetetrahydrofolate Reductase (NADPH2) EC 1.5.1.20

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

10064

Références

Chen, C. J. et al. Homocysteine is a bystander for ST segment elevation myocardial infarction: a case-control study. BMC Cardiovasc Disord. 18, 33 (2018).
doi: 10.1186/s12872-018-0774-8
Ostrakhovitch, E. A. & Tabibzadeh, S. Homocysteine and age-associated disorders. Ageing Res Rev. 49, 144–164 (2019).
doi: 10.1016/j.arr.2018.10.010
Agata Chmurzynska et al. Elderly women: Homocysteine reduction by short-term folic acid supplementation resulting in increased glucose concentrations and affecting lipid metabolism (C677T MTHFR polymorphism). Nutrition 29, 841–844 (2013).
doi: 10.1016/j.nut.2012.09.015
Momin, M. et al. Relationship between plasma homocysteine level and lipid profiles in a community-based Chinese population. Lipids Health Dis. 16, 54 (2017).
doi: 10.1186/s12944-017-0441-6
Ni, J. et al. Association between the MTHFR C677T polymorphism, blood folate and vitamin B12 deficiency, and elevated serum total homocysteine in healthy individuals in Yunnan Province, China. J. Chin. Med. Assoc. 80, 147–153 (2017).
doi: 10.1016/j.jcma.2016.07.005
Jin, W. et al. Association of MTHFR C677T gene polymorphism with metabolic syndrome in a Chinese population: a case–control study. J. Int. Med. Res. 46, 2658–2669 (2018).
Li, M. N. et al. MTHFR C677T gene polymorphism and the severity of coronary lesions in acute coronary syndrome. Medicine (Baltimore) 96, e9044 (2017).
doi: 10.1097/MD.0000000000009044
Luo, Z. et al. Associations of the MTHFR rs1801133 polymorphism with coronary artery disease and lipid levels: a systematic review and updated meta-analysis. Lipids Health Dis 17, 191 (2018).
doi: 10.1186/s12944-018-0837-y
Nakai, K. et al. Correlation between C677T MTHFR gene polymorphism, plasma homocysteine levels and the incidence of CAD. Am J. Cardiovasc Drugs 1, 353–361 (2001).
doi: 10.2165/00129784-200101050-00005
Park, W. C. & Chang, J. H. Clinical Implications of Methylenetetrahydrofolate Reductase Mutations and Plasma Homocysteine Levels in Patients with Thromboembolic Occlusion. Vasc Specialist Int 30, 113–119 (2014).
doi: 10.5758/vsi.2014.30.4.113
Ramkaran, P. et al. Methylenetetrahydrofolate reductase C677T polymorphism is associated with increased risk of coronary artery disease in young South African Indians. Gene 571, 28–32 (2015).
doi: 10.1016/j.gene.2015.06.044
Jerbi, Z. et al. Étude du polymorphisme C677T du gène de la méthylène tétrahydrofolate réductase dans la population tunisienne. Ann Biol. Clin. 63, 487–491 (2005).
Kerkeni, M. et al. Hyperhomocysteinaemia, methylenetetrahydrofolate reductase polymorphism and risk of coronary artery disease. Ann Clin Biochem. 43, 200–206 (2006).
doi: 10.1258/000456306776865232
Ghazouani, L. et al. Homocysteine and methylene-tetrahydrofolate reductase C677T and A1298C polymorphisms in Tunisian patients with severe coronary artery disease. J. Thromb Thrombolysis 27, 191–197 (2009).
doi: 10.1007/s11239-008-0194-1
Abd El-Aziz, T. A. & Mohamed, R. H. Influence of MTHFR C677T gene polymorphism in the development of cardiovascular disease in Egyptian patients with rheumatoid arthritis. Gene 610, 127–132 (2017).
doi: 10.1016/j.gene.2017.02.015
Yamada, K. et al. Effects of common polymorphisms on the properties of recombinant human methylenetetra-hydrofolate reductase. Proc. Natl. Acad. Sci. 98, 14853e8 (2001).
Cohen, E. et al. Gender differences in homocysteine concentrations, a populationbased cross-sectional study. Nutr. Metab. Cardiovasc. Dis. 29, 9e14 (2019).
doi: 10.1016/j.numecd.2018.09.003
Lakkakula, B. V. K. S. Association between MTHFR 677C > T polymorphism and vascular complications in sickle cell disease: A meta-analysis. Transfus Clin Biol. 26, 284–288 (2019).
doi: 10.1016/j.tracli.2019.01.003
Maira Gianneloua et al. Contribution of MTHFR gene variants in lupus related subclinical atherosclerosis. Clin Immunol. 193, 110–117 (2018).
doi: 10.1016/j.clim.2018.02.014
Rassoul, F. et al. Plasma homocysteine levels and C677T methylenetetra-hydrofolate -reductase gene polymorphism in patients with coronary artery disease of different severity. Indian J. Med. Res. 127, 154–158 (2008).
pubmed: 18403793
Li, M. N. et al. MTHFR C677T gene polymorphism and the severity of coronary lesions in acute coronary syndrome. Medicine. 96, e9044 (2017).
doi: 10.1097/MD.0000000000009044
Zhe, Y. G. et al. OLR1, PON1 and MTHFR Gene Polymorphisms, Conventional Risk Factors and the Severity of Coronary Atherosclerosis in a Chinese Han Population. Cell. Physiol. Biochem. 31, 143–152 (2013).
doi: 10.1159/000343356
Xu, H. et al. Plaque image characteristics, hyperhomocysteinemia, and gene polymorphism of homocysteine metabolism-related enzyme (MTHFR C677T) in acute coronary syndrome. Cell. Biochem. Biophys. 66, 403–407 (2013).
doi: 10.1007/s12013-012-9483-6
Alroy, S. et al. Endothelial cell dysfunction in women with cardiac syndrome X and MTHFR C677T mutation. IMAJ 9, 321–325 (2007).
pubmed: 17491230
Morita, H. et al. Genetic polymorphism of 5,10-methylenetetrahydrofolate reductase (MTHFR) as a risk factor for coronary artery disease. Circulation 95, 2032–2036 (1997).
doi: 10.1161/01.CIR.95.8.2032
Bouzidi, N. et al. Relationship of activin A levels with clinical presentation, extent, and severity of coronary artery disease. Anatol J. Cardiol. 18, 402–409 (2017).
pubmed: 29256875 pmcid: 6282897
Gensini, G. G. A more meaningful scoring system for determining the severity of coronary heart disease. Am. J. Cardiol. 51, 606 (1983).
doi: 10.1016/S0002-9149(83)80105-2
Güliz Dirimen, A. et al. Characteristics of Coronary Artery Disease Patients Who Have a Polymorphism in the Cholesterol Ester Transfer Protein (CETP) Gene. In Vivo 33, 787–792 (2019).
doi: 10.21873/invivo.11540

Auteurs

Nadia Bouzidi (N)

University of Monastir, Faculty of Pharmacy, Clinical and Molecular Biology Unit, UR 17ES29, 5000, Monastir, Tunisia. nadiabouzidi1@outlook.fr.

Majed Hassine (M)

University of Monastir, Cardiology A Department Fattouma Bourguiba University Hospital, Cardiothrombosis Research Laboratory, LR12SP16, 5000, Monastir, Tunisia.

Hajer Fodha (H)

University of Monastir, Faculty of Pharmacy, Biochemistry and Molecular Biology Laboratory, Monastir, Tunisia.

Mejdi Ben Messaoud (M)

University of Monastir, Cardiology A Department Fattouma Bourguiba University Hospital, Cardiothrombosis Research Laboratory, LR12SP16, 5000, Monastir, Tunisia.

Faouzi Maatouk (F)

University of Monastir, Cardiology B Department Fattouma Bourguiba University Hospital, Cardiothrombosis Research Laboratory, LR12SP16, 5000, Monastir, Tunisia.

Habib Gamra (H)

University of Monastir, Cardiology A Department Fattouma Bourguiba University Hospital, Cardiothrombosis Research Laboratory, LR12SP16, 5000, Monastir, Tunisia.

Salima Ferchichi (S)

University of Monastir, Faculty of Pharmacy, Clinical and Molecular Biology Unit, UR 17ES29, 5000, Monastir, Tunisia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH